GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » New Journey Health Technology Group Co Ltd (SZSE:002219) » Definitions » Beneish M-Score

New Journey Health Technology Group Co (SZSE:002219) Beneish M-Score : -2.29 (As of May. 25, 2024)


View and export this data going back to 2008. Start your Free Trial

What is New Journey Health Technology Group Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.29 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for New Journey Health Technology Group Co's Beneish M-Score or its related term are showing as below:

SZSE:002219' s Beneish M-Score Range Over the Past 10 Years
Min: -6.66   Med: -2.34   Max: -0.28
Current: -2.29

During the past 13 years, the highest Beneish M-Score of New Journey Health Technology Group Co was -0.28. The lowest was -6.66. And the median was -2.34.


New Journey Health Technology Group Co Beneish M-Score Historical Data

The historical data trend for New Journey Health Technology Group Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

New Journey Health Technology Group Co Beneish M-Score Chart

New Journey Health Technology Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -6.56 -2.82 -3.22 -2.27 -2.43

New Journey Health Technology Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.31 -2.36 -2.42 -2.43 -2.29

Competitive Comparison of New Journey Health Technology Group Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, New Journey Health Technology Group Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


New Journey Health Technology Group Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, New Journey Health Technology Group Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where New Journey Health Technology Group Co's Beneish M-Score falls into.



New Journey Health Technology Group Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of New Journey Health Technology Group Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.1536+0.528 * 1.0908+0.404 * 1.0313+0.892 * 1.1514+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9365+4.679 * -0.037228-0.327 * 0.9653
=-2.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥1,257 Mil.
Revenue was 862.838 + 1083.408 + 900.351 + 821.227 = ¥3,668 Mil.
Gross Profit was 248.5 + 314.088 + 239.417 + 292.094 = ¥1,094 Mil.
Total Current Assets was ¥2,027 Mil.
Total Assets was ¥6,188 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,647 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥438 Mil.
Total Current Liabilities was ¥3,007 Mil.
Long-Term Debt & Capital Lease Obligation was ¥763 Mil.
Net Income was 24.405 + -2.642 + -23.586 + 35.251 = ¥33 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 10.958 + 111.666 + 54.101 + 87.082 = ¥264 Mil.
Total Receivables was ¥946 Mil.
Revenue was 785.496 + 829.027 + 810.471 + 760.418 = ¥3,185 Mil.
Gross Profit was 234.327 + 323.502 + 229.027 + 249.634 = ¥1,036 Mil.
Total Current Assets was ¥1,963 Mil.
Total Assets was ¥5,833 Mil.
Property, Plant and Equipment(Net PPE) was ¥2,486 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥406 Mil.
Total Current Liabilities was ¥3,360 Mil.
Long-Term Debt & Capital Lease Obligation was ¥322 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1256.82 / 3667.824) / (946.195 / 3185.412)
=0.342661 / 0.29704
=1.1536

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1036.49 / 3185.412) / (1094.099 / 3667.824)
=0.325386 / 0.298296
=1.0908

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (2027.036 + 2647.138) / 6188.268) / (1 - (1963.096 + 2485.974) / 5832.948)
=0.244672 / 0.237252
=1.0313

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=3667.824 / 3185.412
=1.1514

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 2485.974)) / (0 / (0 + 2647.138))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(438.215 / 3667.824) / (406.402 / 3185.412)
=0.119475 / 0.127582
=0.9365

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((763.183 + 3007.215) / 6188.268) / ((321.708 + 3359.894) / 5832.948)
=0.609282 / 0.631173
=0.9653

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(33.428 - 0 - 263.807) / 6188.268
=-0.037228

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

New Journey Health Technology Group Co has a M-score of -2.29 suggests that the company is unlikely to be a manipulator.


New Journey Health Technology Group Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of New Journey Health Technology Group Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


New Journey Health Technology Group Co (SZSE:002219) Business Description

Traded in Other Exchanges
N/A
Address
Duyiyi Industrial Park, Wangba, Kang County, Gansu Province, Longnan, CHN, 610000
New Journey Health Technology Group Co Ltd formerly Hengkang Medical Group Co Ltd is engaged in research, development, and manufacturing of natural herbal medicines. The company's products include analgesic and haemostatic drugs.
Executives
Song Li Hua Directors, executives
Yu Mei Directors, executives
Wang Yong Executives
Zuo Bin Lin Executives
Tang Can Director
Duan Zhi Ping Director
Zhou Xian Min Director
Guo Kai Executives
Xie Hai Executives
Shi Xiao Ming Executives
Li Yu Fei Supervisors
Huang Rui Directors, executives
Pan Yu Supervisors
Liao Li Dong Executives

New Journey Health Technology Group Co (SZSE:002219) Headlines

No Headlines